VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Ellis on Hopeful ER+/HER2- Breast Cancer Paradigms

Matthew J. Ellis, MD, PhD
Published: Wednesday, Sep 14, 2011

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, explains that he anticipates a paradigm between other rare forms of cancer and estrogen receptor (ER) positive/HER2-negative breast cancer.

Ellis hopes to find something similar to the use of imatinib for Ph+ CML. In this case a fusion gene, BCR-ABL, activates the tumor cells, by inhibiting the mutation you can get rid of the tumor. In breast cancer an example would be Herceptin and other agents for HER2 amplifications.

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, explains that he anticipates a paradigm between other rare forms of cancer and estrogen receptor (ER) positive/HER2-negative breast cancer.

Ellis hopes to find something similar to the use of imatinib for Ph+ CML. In this case a fusion gene, BCR-ABL, activates the tumor cells, by inhibiting the mutation you can get rid of the tumor. In breast cancer an example would be Herceptin and other agents for HER2 amplifications.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x